Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
LAPATINIB tablets, for oral use These highlights do not include all the information needed to use LAPATINIB TABLETS safely and effectively. See full prescribing information for LAPATINIB TABLETS. Initial U.S. Approval: 2007
Medication labelWhy this: Advisory · dailymed-prescription
Lapatinib tablets are indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
- generic_name
- lapatinib
- product_names
- Lapatinib
- ndc
- 42291-035, 0480-3237, 42291-035-15
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en